Etravirine TMC-125 CAS 269055-15-4 Assay ≥99.0% (HPLC) API Factory High Purity

Short Description:

Chemical Name: Etravirine (TMC-125)

CAS: 269055-15-4

Appearance: White Solid Powder

Assay: ≥99.0% (HPLC)

Etravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used for the treatment of HIV

API High Quality, Commercial Production

Inquiry: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Manufacturer with High Purity and Stable Quality
Chemical Name: Etravirine (TMC-125)
CAS: 269055-15-4
API High Quality, Commercial Production

Chemical Properties:

Chemical Name	Etravirine
Synonyms	TMC-125
CAS Number	269055-15-4
CAT Number	RF-API54
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C20H15BrN6O
Molecular Weight	435.28
Density	1.439 g/cm3
Shipping Condition	Under Ambient Temperature
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	White Solid Powder
Identification	By IR, HPLC
Melting Point	211.0~216.0℃
Water Content	≤0.50%
Residue on Ignition	≤0.20%
Heavy Metals	≤20ppm
Any Single Impurity	≤0.50%
Total Impurities	≤1.0%
Assay	≥99.0% (HPLC)
Test Standard	Enterprise Standard

Package & Storage:

Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.

Advantages:

FAQ:

Application:

Etravirine (TMC-125) (CAS 269055-15-4) is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) used for the treatment of HIV. It is indicated for use in combination with other antiretroviral agents for treating HIV-1 infection in treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to the currently available NNRTIs and other antiretroviral agents. The NNRTIs, along with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs/NtRTIs), are important components of the combination regimens currently used to treat HIV-1 infection. The NRTIs/NtRTIs act by competing with the natural nucleotide substrates of reverse transcriptase for incorporation into viral DNA and subsequent chain termination. By contrast, the NNRTIs bind to an allosteric site of the enzyme and disrupt the DNA polymerase function by inducing conformational changes to the catalytic site.